Targeting GM-CSF in rheumatological conditions: risk of PAP - Authors' reply

Affiliations

• ¹ Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA.
• ² Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
• ³ ImmunoInflammation, GlaxoSmithKline, Stevenage SG1 2NY, UK.
• ⁴ Department of Internal Medicine 3, University of Erlangen-Nurnberg and Universitatsklinikum Erlangen, Erlangen, Germany.
• ⁵ Statistics, GlaxoSmithKline, Stevenage SG1 2NY, UK.
• ⁶ Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Stevenage SG1 2NY, UK.
• ⁷ ImmunoInflammation, GlaxoSmithKline, Middlesex, UK.
• ⁸ Research and Development, GlaxoSmithKline, Stevenage SG1 2NY, UK. Electronic address: tak.paulpeter@gmail.com.